Eric Lefkofsky is on a Mission to Bring Cancer under Control by Data-Enabled Precision Medicine


Eric Lefkofsky, the CEO and co-founder of Tempus, is on a mission to bring efficient cancer treatment solutions through data-enabled precision medicine system. It should be noted that almost 40 percent of American adults are experiencing cancer diagnosis during their life time. Also a significant increase in the number of patients expected from the current 14.5 million to 19 million by 2024. However, Lefkofsky and his Tempus ensure that future would not be as bad as the numbers considering his efforts for data-enabled precision medicine. Previously, his personal experience shocked him that there was no data collection and streamlined analysis on cancer treatments and its response information with respect to molecular data of the patients. Lefkofsky learned that if he could ensure data collection based on digital technology that would save millions of cancer patients. That is where Tempus was born and read full article.

 

The firm is on a mission to change the way cancer care is provided. It has developed a platform that analyzes patients’ molecular and clinical data. It faced few initial hurdles including expensive analytical software and inefficient information storage system considering most physicians go for progress notes. To overcome this, Lefkofsky led Tempus to develop a software with optical character recognition and natural language processing options. In the end, the text fields with pertinent notes transform to structured data for using it in advanced cancer treatment. While coming to molecular data, it is captured through human genome sequencing. With the data captured by Tempus, the physicians can refer the historical cancer treatments, its effectiveness with respect to molecular data, and go for more accurate and effective treatment methods and learn more about Eric.

 

Eric Lefkofsky is also the Chairman and co-founder of Groupon and co-founder of a number of firms including Mediaocean, InnerWorkings, Echo Global Logistics, Lightbank, and Uptake. He is also known for various philanthropic initiatives and founded Lefkofsky Foundation to support educational, scientific, and charitable organizations around the world.

 

Lefkofsky completed his graduation from the University of Michigan and secured his J.D. from the Law School of the same university. He is serving on the boards of Children’s Memorial Hospital located in Chicago and the Chicago Art Institute.

Oncotarget publishes another insightful article on cellular Rejuvenation


Every scholar’s goal is to have their work published by top journals in the industry and shared widely among other scholars in their respective fields and beyond. For several years, Oncotarget leading in providing a conducive platform for sharing scientific findings widely and rapidly.

Contrary to what many people believe, Oncotarget doesn’t only focus on oncology related research findings, but also incorporate other fields such as immunology, pathology, cell death, neuroscience, autophagy, neurotarget, and circadian rhythm among others. Most of the articles that are published in this great medical journal are, however, based on various applications of clinical and general science to fight diseases.

Among the many articles that have been by this journal, one that stands out in the cellular rejuvenation field is the 2015’s Nutritional Perspective/Outlook on Cellular Rejuvenation. Authored by HuebbePatrcia, SchloesserAnke, and Rimbach Gerald, the article posits that dietary energy intake restriction is one of the most robust interventions for extending lifespan and decelerating aging processes. According to authors, given the nutrient-dense and high calorie diets that are consumed in the Western societies and the accompanies health issues that follows, it is sound to suggest that dietary restriction will go a long way in curbing cellular senescence without manipulating macronutrient composition.

The cellular rejuvenation article is not the only article that has catapulted Oncotarget to the limelight. In fact, it can be considered as the proverbial drop in the ocean. Over the years, the journal has received a lot of media attention because of its remarkable works, which have seen many of its management and members awarded a variety of prestigious prizes to know more visit @:  http://www.bioxbio.com/if/html/ONCOTARGET.html click here.

One unique feature about this Oncotarget is the fact that they involve their authors in every step of manuscript evaluation—all of which are primarily pegged on merit and not the author’s age, gender, religion, or race. Their editors’ decisions are also impartial as they are not controlled by agencies or polices outside those set by the journal. Additionally, the publication strives to keep every article that is submitted to them as a private property until it is published.

How Eric Lefkofsky is Approaching Healthcare Data with ‘Tempus’


The team at the new tech start up Tempus are focused on life changing innovations within the medical research field. Tempus was co founded by Eric Lefkofsky who is most well known for his work on his other company, Groupon. Lefkofsky was drawn to creating Tempus after his wife was diagnosed with breast cancer. During her trying times, and many visits to the hospital, Lefkofsky saw how impossibly complicated sending and receiving data records was. Patient data is the lifeblood of innovation for medicine and when doctors can’t access that data, people suffer.

The core concept surrounding Tempus is to take existing digital medical records, or EMRs, and push them through a data aggregate database. There the information will be verified, sourced, and sent into another pool that can be used by doctors, patients, and other medical professionals around the world. The need for access to this data cannot be understated and Lefkofsky used his own experiences to inform Lefkofsky work at Tempus.

Lefkofsky spoke at at the Fortune Brainstorm Health conference, located in San Diego this past May, in order to highlight the importance of his work with Tempus. Lefkofsky pointed to data as the primary focus of his speech, “You need therapeutic and outcome response data.” Medical research is incredibly tough to parse and that is why a surplus of information and accessibility is a primary concern. Look at a drug like Herceptin and consider that it is effective in X amount of patients. Why does it not work for the other patients? Aggregated data can help answer these tough questions.

Eric Lefkofsky has a long history of successful work in the tech industry. He co-founded Tempus and worked hard to bring Groupon to life. Leftkofsky also has a fascinating history of work within Chicago. Lefkofsky is a Chairman for the prestigious Steppenwolf Theatre Company as well as an adjunct professor at the University of Chicago. Lefkofsky also makes sure to give back through his charitable group, the Lefkofsky Family Foundation. Lefkofsky’s foundation services communities with initiatives that aim to enhance their lives and improve the area that they live in.

for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/